Assessing risk: Data from montelukast clinical trials.
Kelsay
Kimberly
K
D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001249:Asthma / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D003521:Cyclopropanes; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology; D011804:Quinolines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D013405:Suicide; D013440:Sulfides
D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast